PengL

[Lingling Tian @LinglingTian123]

Immunotherapy for #TCellMalignancies raises unique challenges-from antigen overlap to CAR‑T fratricide. This Special Collection brings together translational and early clinical insights addressing these barriers.
Submissions open until 29 Jan 2027
https://t.co/XbDcT9hIdC

[iMeta @iMetaScience]

Navigating the future of nano‐pesticides: A perspective on design, efficacy, mechanisms, and environmental stewardship
🌱Nano-pesticides are reshaping crop protection toward sustainable agriculture.
https://t.co/zeT5XEpC8r

[iMeta @iMetaScience]

Two stable gut microbiome guilds predict liver tumor class and treatment responses

⚙️ Functionally opposing microbial guilds highlight an ecological basis for tumor progression and clinical outcomes. #Hepatocellular @WileyHealth
https://t.co/QVa6EJm3wO

[Therapeutic Advances in Medical Oncology @TAMedOncol]

Real‑world, 8‑year multicancer study of lenvatinib shows manageable long‑term use across DTC, AdCC, HCC & EC. Notably, BMI declined during treatment (p=0.045), highlighting the need for closer monitoring in low‑BMI patients.
🔗 https://t.co/hWuTnmAyHU
#Lenvatinib @elenacolomboMD

[Therapeutic Advances in Medical Oncology @TAMedOncol]

French consensus published in Ther Adv Med Onc-provide practical, real‑world guidance to prevent and manage hematologic toxicities from PARPis in metastatic PC-an area of growing need.
🔗 Full article: https://t.co/AMRFwbCzfa
#ProstateCancer #mCRPC #PARPInhibitors #Oncology

[Therapeutic Advances in Medical Oncology @TAMedOncol]

Real‑world evidence in Ther Adv Med Onc shows nal‑IRI/5‑FU/LV significantly improves OS in pancreatic adenocarcinoma (28.0 vs 18.3 months) despite higher cost (ICER $33,285/LYG). 🔗https://t.co/U97g43SisO
#PancreaticCancer #GIOnc #RealWorldEvidence #HealthEconomics

[iMeta @iMetaScience]

🚀 317 R scripts for biomedical research, no coding barrier
⏱️ Standardized design saves time
✅ Verified, annotated, reproducible
🧬 Covers #scRNA-seq, spatial #transcriptomics, #ML & more
Developed by @guangchuangyu and @PengL_Robin
🔗https://t.co/7RQbAOmrX2
#Bioinformatics

[BMC Medicine @BMCMedicine]

🚨Lin et al. discuss the critical role of clinical trials in medical advancements, emphasizing their importance in verifying treatment efficacy and ensuring patient safety through rigorous study designs and data collection methods https://t.co/XE8lNgJ0w2 @PengL_Robin #BMCMedicine

[iMeta @iMetaScience]

🎉 Milestone for #iMetaMed!
We’ve just published our first paper, FastUKB 🚀
iMetaMed advances research in multi-#omics, big data, #AI & precision medicine in #healthcare.
More here: https://t.co/xS7vvLkl6z @PengL_Robin

[PengL @PengL_Robin]

https://t.co/jnD1W5lK45

[Professor Azeem Majeed @Azeem_Majeed]

By capturing data across five spatial hierarchies (global, regional, national, subnational, local), our analysis reveals striking disparities in Covid-19 incidence, prevalence, mortality and disability; providing data to improve pandemic preparedness. https://t.co/jli80M3oUS

[iMeta @iMetaScience]

Bacterial load in #meconium https://t.co/A12GxPEtAi
#microbiome #GutHealth

[iMeta @iMetaScience]

Gut #microbiota reshapes #cancer #immunotherapy efficacy: Mechanisms and therapeutic strategies https://t.co/GrK4dRCqz6
#microbiome #tumor #MedTwitter

[iMeta @iMetaScience]

🚨 Exciting news! We’re launching iMetaMed, a new sub-journal of the iMeta series @iMetaScience to #medicine, #health, and #biotechnology.
It aims to be a high-quality platform for global researchers and clinicians.
🔗 Learn more: https://t.co/5xqrmqOkFU
@WileyHealth @WileyBiomedical @wileymicrobio

[iMeta @iMetaScience]

Non‐differential gut #microbes contribute to #hypertension and its severity through co‐abundances: A multi‐regional prospective #cohort study https://t.co/RHA5P9dYpd
#microbiome #cardiovascular #MedTwitter @wileymicrobio @WileyBiomedical @WileyHealth

[iMeta @iMetaScience]

Gut #microbiota in treating #inflammatory digestive diseases: Current challenges and therapeutic opportunities https://t.co/4nU5rK9N3N
#microbiome @wileymicrobio @WileyBiomedical @WileyHealth

[iMeta @iMetaScience]

MicroRNA‐microbiota interactions: Emerging strategies for modulating intestinal homeostasis and enhancing host health #iMetaOmics https://t.co/BtieZxsYhS
#microbiome #microRNA #guthealth #microbiota
@wileymicrobio @WileyHealth @WileyBiomedical

[PengL @PengL_Robin]

🔬 Our new review in Journal of Translational Medicine @BioMedCentral explores the mechanisms behind Second Primary Cancers (SPCs) - a major threat to cancer survivors

Key findings:

SPCs develop through multiple pathways including:
• Genomic changes
• Stromal cell alterations
• Immune suppression
• Hormonal factors
🧬 Novel research directions:
• Intratumoral microbes
• Single-cell multi-omics
• Metabolomics

Read more: [https://t.co/chyt0cLYbI]

#CancerResearch #Oncology #Cancer

[Cell Proliferation @BISCRM]

This review provides a comprehensive synthesis of the current understanding of mesenchymal stem cell-derived exosomes (MSC-Exos) , underscoring their role as a novel and potent therapeutic strategy against the intricate challenges of age-related diseases. https://t.co/AiUUHsOBiB

[Cell Proliferation @BISCRM]

This review provides a comprehensive overview of the state-of-the-art in non-viral CAR-NK cell engineering, highlighting its potential to revolutionize cancer treatment.
https://t.co/x2zh9upSNg